v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Oct. 31, 2022
Oct. 31, 2021
Cash flows from operating activities    
Net loss $ (96,919,000) $ (89,799,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 12,567,000 9,889,000
Amortization of deferred sales commissions 14,819,000 11,353,000
Amortization (accretion) of marketable securities purchased at a premium (discount) 1,415,000 2,156,000
Stock-based compensation, net of amounts capitalized 49,933,000 39,127,000
Non-cash operating lease cost 2,998,000 3,132,000
Other (217,000) (1,852,000)
Changes in operating assets and liabilities    
Accounts receivable (6,922,000) 1,910,000
Prepaid expenses (18,000) (133,000)
Other assets (538,000) 1,104,000
Deferred sales commissions (14,975,000) (16,252,000)
Accounts payable 10,256,000 4,283,000
Accrued expenses and other current liabilities (2,594,000) 1,806,000
Deferred revenue 10,764,000 16,436,000
Operating lease liabilities (3,328,000) (3,371,000)
Other liabilities 594,000 265,000
Net cash used in operating activities (22,165,000) (19,946,000)
Cash flows from investing activities    
Purchases of marketable securities (184,996,000) (359,587,000)
Maturities of marketable securities 182,563,000 57,958,000
Sales of marketable securities 25,102,000 15,480,000
Purchases of property and equipment (386,000) (1,799,000)
Capitalized internal-use software costs (986,000) 0
Cash paid for acquisitions, net of cash and restricted cash acquired 0 (40,340,000)
Net cash provided by (used in) investing activities 21,297,000 (328,288,000)
Cash flows from financing activities    
Payments of deferred offering costs 0 (93,000)
Proceeds from employee stock purchase plan 2,831,000 4,725,000
Proceeds from exercise of common stock options 11,479,000 17,974,000
Cash paid for holdback consideration in connection with acquisitions (456,000) 0
Net cash provided by financing activities 13,854,000 22,606,000
Effect of exchange rate changes on cash and cash equivalents (1,310,000) (174,000)
Change in cash and cash equivalents and restricted cash 11,676,000 (325,802,000)
Beginning of period 80,286,000 404,440,000
End of period 91,962,000 78,638,000
Supplemental disclosures of cash flow information    
Cash paid for income taxes 1,804,000 831,000
Cash paid for interest 68,000 63,000
Supplemental non-cash investing and financing information    
Vesting of early exercised options 33,000 148,000
Common stock and assumed awards issued as consideration for acquisitions 0 30,499,000
Unpaid cash consideration for acquisitions 0 456,000
Stock-based compensation capitalized as internal-use software costs 336,000 0
Property and equipment accrued but not yet paid 0 40,000
Reconciliation of cash, cash equivalents, and restricted cash to consolidated balance sheets    
Cash and cash equivalents 91,662,000 78,288,000
Restricted cash included in other current assets 300,000 350,000
Total cash, cash equivalents, and restricted cash $ 91,962,000 $ 78,638,000